Improving quality of life of Parkinson’s disease patients by Quantitative Cognit...
Improving quality of life of Parkinson’s disease patients by Quantitative Cognitive Testing
Parkinson’s disease is dominated by motor symptoms such as tremor, bradykinesia and postural instability. However, over 90% of all patients develop cognitive impairment including deterioration of learning, memory and decision maki...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
E-SPACE
European Standardised Process Approach to Cognitive Evaluati...
188K€
Cerrado
ID-earlyMCI
Objective home based EEG prediction of aMCI Identification...
185K€
Cerrado
NPAD
Multiregional rtfMRI Neurofeedback for the Prevention of Alz...
158K€
Cerrado
NEUROCOG
Neural correlates of narrative discourse in mild cognitive i...
265K€
Cerrado
PSI2012-32441
CAMBIOS CEREBRALES ESTRUCTURALES Y FUNCIONALES ASOCIADOS A L...
53K€
Cerrado
TEC2011-22987
EXTRACCION, SELECCION Y CLASIFICACION DE CARACTERISTICAS DE...
130K€
Cerrado
Información proyecto ParSyncR
Duración del proyecto: 17 meses
Fecha Inicio: 2023-11-01
Fecha Fin: 2025-04-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Parkinson’s disease is dominated by motor symptoms such as tremor, bradykinesia and postural instability. However, over 90% of all patients develop cognitive impairment including deterioration of learning, memory and decision making. Current treatments focus on motor symptoms and offer at best moderate improvement of cognitive functions. Alleviating cognitive symptoms could dramatically increase quality of life of patients. Therefore, we propose to apply a behavioral test of fine decision making combined with electroencephalography and electromyography measurements to quantitatively assess complex aspects of cognitive function, including inhibitory control, learning by reinforcement and decision making under conflict. This Quantitative Cognitive Testing (QCT) can be employed to improve Parkinson’s disease therapy based on regular feedback. Moreover, the method can be extended to other domains of neurodegenerative dementias. We foresee that the application of QCT can facilitate the development of telemedicine packages, thus reducing hospital visits and patient-doctor contacts. Under this PoC, we propose to validate equipment we developed de novo, conduct proof of concept experiments, extend IPR protection, and explore commercialization strategies. We believe that QCT can help achieve the best possible cognitive function, which would improve the quality of life of patients and their families. It could also reduce disease-related cost burden on health care systems and society, making it appealing to health providers.